Education
About Us
Working with TipRanks
Follow Us
C4 Therapeutics, Inc. (CCCC)
:CCCC
CCCC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.09 - $7.66
Previous CloseN/A
Volume165.25K
Average Volume (3M)1.21M
Market Cap
$99.41M
Enterprise Value$345.68M
Total Cash (Recent Filing)$215.09M
Total Debt (Recent Filing)$64.37M
Price to Earnings (P/E)―
Beta3.32
Next Earnings
Aug 06, 2025EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.37
Shares Outstanding71,007,080
10 Day Avg. Volume1,650,864
30 Day Avg. Volume1,206,420
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.00
Price to Sales (P/S)0.00
P/FCF Ratio-2.59
Enterprise Value/Market Cap3.48
Enterprise Value/Revenue2.50
Enterprise Value/Gross Profit10.19
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$3.50Price Target Upside150.00% Upside
Rating ConsensusHold
Number of Analyst Covering0
C4 Therapeutics News
PremiumCompany Announcements
C4 Therapeutics Holds Annual Stockholders Meeting
PremiumCompany Announcements
C4 Therapeutics Reports Q1 2025 Financial Results
PremiumCompany Announcements
C4 Therapeutics Updates on Cemsidomide Clinical Trial
PremiumCompany Announcements
C4 Therapeutics Board Member Bruce Downey Retires
Bulls Say, Bears Say
Bulls Say
Partnership OpportunitiesManagement intends to partner cemsi to maximize value, which could result in a rally of shares upon an announcement.
Product PotentialCFT1946 has the potential to replace BRAF inhibitors and be CCCC's first wholly-owned commercial product.
ValuationThe company's valuation at an EV of ~$50MM suggests a significant opportunity for growth, as the market currently assigns no value to certain promising programs.
Bears Say
Market CompetitionCompetitors in the market could challenge the potential growth of CFT1946 and its ability to replace existing BRAF inhibitors.
Regulatory UncertaintyThe process of determining the dosing regimen for cemsi highlights challenges related to regulatory approval and competitive profiling.
Ownership Overview
3.13% Insiders
15.23% Mutual Funds
54.06% Other Institutional Investors
17.92% Public Companies and Individual Investors
CCCC FAQ
What was C4 Therapeutics, Inc.’s price range in the past 12 months?
C4 Therapeutics, Inc. lowest stock price was $1.08 and its highest was $7.66 in the past 12 months.
What is C4 Therapeutics, Inc.’s market cap?
C4 Therapeutics, Inc.’s market cap is $99.41M.
When is C4 Therapeutics, Inc.’s upcoming earnings report date?
C4 Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2025 which is in 37 days.
How were C4 Therapeutics, Inc.’s earnings last quarter?
C4 Therapeutics, Inc. released its earnings results on May 07, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.442 by $0.072.
Is C4 Therapeutics, Inc. overvalued?
According to Wall Street analysts C4 Therapeutics, Inc.’s price is currently Undervalued.
Does C4 Therapeutics, Inc. pay dividends?
C4 Therapeutics, Inc. does not currently pay dividends.
What is C4 Therapeutics, Inc.’s EPS estimate?
C4 Therapeutics, Inc.’s EPS estimate is -0.4.
How many shares outstanding does C4 Therapeutics, Inc. have?
C4 Therapeutics, Inc. has 71,007,080 shares outstanding.
What happened to C4 Therapeutics, Inc.’s price movement after its last earnings report?
C4 Therapeutics, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.442. Following the earnings report the stock price went up 6.383%.
Which hedge fund is a major shareholder of C4 Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CCCC
C4 Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.50 (150.00% Upside)
$3.50 (150.00% Upside)
Blogger Sentiment
Neutral
CCCC Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 5.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.2%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.69%
12-Months-Change
Fundamentals
Return on Equity
-45.55%
Trailing 12-Months
Asset Growth
-19.79%
Trailing 12-Months
Company Description
C4 Therapeutics, Inc.
C4 Therapeutics (CCCC) is a biotechnology company focused on pioneering a new class of targeted protein degradation (TPD) medicines to treat cancer and other diseases. Operating within the biopharmaceutical sector, the company utilizes its proprietary technology platform, TORPEDO, to develop small-molecule drugs that selectively degrade disease-causing proteins. By harnessing the body's natural protein disposal system, C4 Therapeutics aims to address challenging targets that have been deemed undruggable by traditional approaches.
Technical Analysis
Zentalis Pharmaceuticals
―
Vor Biopharma
―
Climb Bio
―
Zura Bio
―
Kyverna Therapeutics, Inc.
―